QR-koda

Use of vedolizumab in pediatric intestinal transplant rejection

Background: Blockade of α4β7 integrin cell adhesion receptors on activated lymphocytes with the monoclonal antibody vedolizumab (VDZ) is efficacious in treatment of inflammatory bowel disease and most probably intestinal graft versus host disease (GVHD) after stem cell transplantation. Recently, the...

Olles dieđut

Furkejuvvon:
Váldodahkkit: Shahira Ghobrial, Dimitrios Moris, Carolina Rumbo, Stuart S. Kaufman, Gabriel Gondolesi, Dong Hyang Kwon, Yoshinori Takeda, Nada Yazigi, Udeme D. Ekong, Thomas M. Fishbein, Cal S. Matsumoto, Alexander Kroemer, Khalid Khan
Materiálatiipa: Artigo
Giella:Inglês
Almmustuhtton: Elsevier 2026-01-01
Ráidu:Intestinal Failure
Fáttát:
Intestinal transplant
Acute rejection
Vedolizumab
Integrins
Liŋkkat:http://www.sciencedirect.com/science/article/pii/S2950456225003057
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid